SIRPA and cancer: In summary, our research underscores the dual-targeting proficiency of the small-molecule compound SMC18 against both the CD47/SIRPα and PD-1/PD-L1 pathways, bridging innate and adaptive immunity and thus providing a promising candidate for cancer immunotherapy.